Anti-anaemia Potential and Safety of Morinda lucida Leaf Extracts in Balb/c Mice Induced with Rhabdomyosarcoma Cells
No Thumbnail Available
Date
2017-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Anaemia, a major health challenge, results from factors including
dietary deficiencies and malaria. Although reports from previous
studies show that Morinda lucida is effective in the treatment of
anaemia resulting from these conditions, little information exist to
suggest its beneficial effects in treating anaemia resulting from cancer.
This study therefore examined the anti-anaemia potential of M. lucida
leaf extracts in Balb/c mice inoculated with rhabdomyosarcoma (RD)
cells. Forty mice inoculated intra-peritoneally with RD cells were
randomly divided into eight groups: A (untreated); Treatment groups
—B1, B2 and B3 (100, 200 and 300 mg/kg aqueous M. lucida extracts
respectively); C1, C2 and C3 (100, 200 and 300 mg/kg M. lucida
ethanolic extractsrespectively) and D (Cisplatin).Themice were treated
for 2 weeks and thereafter, blood samples were collected through the
orbital sinus for haematological and serum biochemical analyses.
ComparedwithgroupA(3.25±0.03), ethanolic leaf extractsofM.lucida
3
increasedwhite blood cell count(x10 ul)significantly (p?0.05)in groups
C1,C2, andC3 (5.45±0.03, 6.00±0.05, and 5.60±0.10 respectively) but
there was no significantincrease of the packed cell volume in groups C
andE.Comparedwith groupA, aspartate aminotransferase (AST)levels
were significantly lower in all treatment groups, and alkalinephosphatase
levels(ALP)significantly lower in group B. The treatments therefore did
not improve all haematological parameters in RD cell-bearing mice but
elicited increased immune responses, were safe at the doses administered
andconsequentlymaybebeneficialincancer therapy.
Description
Keywords
Anaemia, Cancer, Safety, Morinda lucida, Haematological parameters